Stay updated with breaking news from Lars Backsell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
NorthX Biologics appoints industry veterans to its board of directors - read this article along with other careers information, tips and advice on BioSpace
Roar BidCo's outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms On 14 December 2020, EQT IX 1 2 ("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo (the "Offer"). An offer document relating to the Offer was made public on 17 December 2020 (the "Offer Document"). The Offer was subsequently incr...
Electrolux Nomination Committee's proposal for election of board members STOCKHOLM, Feb. 1, 2021 /PRNewswire/ — In preparation for the Electrolux Annual General Meeting on March 25, Electrolux Nomination Committee has decided to propose the re-election of all board members except Kai Wärn, who has declined re-election. Staffan Bohman is proposed to be re-elected as Chairman of the Board of Directors, and Petra Hedengran, Henrik Henriksson, Ulla Litzén, Karin Overbeck, Fredrik Person, David Porter and Jonas Samuelson as Board Members. The Nomination Committee comprises Johan Forssell (...
By Reuters Staff 1 Min Read STOCKHOLM (Reuters) - Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT raised its bid to 232 crowns per share from the 220 crowns it had offered in December. “We consider this revised offer to be highly compelling for Recipharm’s shareholders,” EQT partner Erika Henriksson said in a statement. EQT added that the bid would not be increased further. Recipharm’s board of directors said in a separate statement they unanimously recommend...